Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL
kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The …

BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in
Philadelphia chromosome-positive (Ph+) leukemia is effectively managed with several …

Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

BCR-ABL1 kinase domain mutations can confer resistance to first-and second-generation
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies …

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic
myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to …

Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development
of resistance continues to challenge the treatment of this disease. Mutations within the …

Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook
for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl …

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more
potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL …